MacroGenics, Inc. (NASDAQ: MGNX) Starts Presentation at 29th Annual ROTH Conference
MacroGenics (NASDAQ: MGNX) is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases. Its advanced clinical product candidate is Margetuximab, a monoclonal antibody that is in Phase III clinical trial, which targets human epidermal growth factor receptor 2-expressing tumors, including certain types of breast and gastroesophageal cancers. The company also develops Enoblituzumab, an antibody that is in phase 1 clinical trial as monotherapy in multiple dose expansion cohorts; and MGD006, a DART molecule that targets CD123 and CD3.…







